Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00027638 |
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.
Condition | Intervention | Phase |
---|---|---|
Gastrointestinal Carcinoid Tumor Islet Cell Tumor Lung Cancer Neoplastic Syndrome |
Drug: thalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) |
Study Start Date: | March 2001 |
OBJECTIVES:
OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed low-grade neuroendocrine tumors
At least 1 bidimensionally measurable lesion by CT scan or MRI
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 |
Study Chair: | Leonard B. Saltz, MD | Memorial Sloan-Kettering Cancer Center |
Study ID Numbers: | CDR0000069051, MSKCC-01027, NCI-G01-2029 |
Study First Received: | December 7, 2001 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00027638 |
Health Authority: | United States: Federal Government |
metastatic gastrointestinal carcinoid tumor recurrent gastrointestinal carcinoid tumor gastrinoma insulinoma recurrent islet cell carcinoma |
WDHA syndrome somatostatinoma pancreatic polypeptide tumor glucagonoma pulmonary carcinoid tumor |
Thoracic Neoplasms Thalidomide Gastrointestinal Diseases Pancreatic Neoplasms Pancreatic Polypeptide Respiratory Tract Diseases Lung Neoplasms Neoplasms, Germ Cell and Embryonal Neuroepithelioma Endocrine Gland Neoplasms Digestive System Neoplasms Carcinoma, Islet Cell Serotonin Syndrome Insulinoma Endocrine System Diseases |
Adenoma, Islet Cell Malignant Carcinoid Syndrome Carcinoid syndrome Recurrence Neuroendocrine Tumors Carcinoma Carcinoid tumor Neuroectodermal Tumors Gastrinoma Digestive System Diseases Lung Diseases Pancreatic Diseases Gastrointestinal Neoplasms Carcinoid Tumor Endocrinopathy |
Anti-Infective Agents Respiratory Tract Neoplasms Neoplasms by Histologic Type Disease Immunologic Factors Antineoplastic Agents Growth Substances Neoplasms, Nerve Tissue Physiological Effects of Drugs Angiogenesis Inhibitors Immunosuppressive Agents |
Pharmacologic Actions Anti-Bacterial Agents Neoplasms Neoplasms by Site Pathologic Processes Therapeutic Uses Syndrome Growth Inhibitors Angiogenesis Modulating Agents Leprostatic Agents |